Submitted by Anonymous (not verified) on 9 February 2026 - 16:46
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 3, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 3, Status: Authorised